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Abstract: Transit amplification (TA), a state of combined, rapid proliferative expansion and
differentiation of stem cell-descendants, remains poorly defined at the molecular level. The Polycomb
Repressive Complex 1 (PRC1) protein BMI1 has been localized to TA compartments, yet its exact
role in TA is unclear. PRC1 proteins control gene expression, cell proliferation and DNA-damage
repair. Coordination of such DNA-templated activities during TA is predicted to be crucial to support
DNA replication and differentiation-associated transcriptional programming. We here examined
whether chondrogenesis provides a relevant biological context for synchronized coordination of
these chromatin-based tasks by BMI1. Taking advantage of a prominently featuring TA-phase
during chondrogenesis in vitro and in vivo, we here report that TA is completely dependent on
intact PRC1 function. BMI1-depleted chondrogenic progenitors rapidly accumulate double strand
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DNA breaks during DNA replication, present massive non-H3K27me3-directed transcriptional
deregulation and fail to undergo chondrogenic TA. Genome-wide accumulation of Topoisomerase
2α and Geminin suggests a model in which PRC1 synchronizes replication and transcription during
rapid chondrogenic progenitor expansion. Our combined data reveals for the first time a vital
cell-autonomous role for PRC1 during chondrogenesis. We provide evidence that chondrocyte
hyper-replication and hypertrophy represent a unique example of programmed senescence in vivo.
These findings provide new perspectives on PRC1 function in development and disease.
Keywords: polycomb; topoisomerase; transit amplification; chromatin; DNA replication;
transcription; chondrogenesis; differentiation; DNA damage; hypertrophy; senescence
1. Introduction
Throughout development, the cooperative action of Polycomb Repressive Complexes (PRCs) and
their counterparts the Trithorax group proteins (TrxG) is thought to constitute part of an epigenetic
transcriptional memory, vital for maintenance of cell identity [1–5]. Many PRC1-mutants display
antero-posterior (A–P) patterning defects in insect and rodent models as a result of failing Hox gene
expression-boundary maintenance. In mice, such defects are manifested as skeletal deformations,
which are exacerbated by compound mutation [6]. In addition, PRC1-mutations are known to cause
defects in DNA replication in Drosophila melanogaster syncytial larvae through as yet unknown
mechanisms [7,8]. PRC1 proteins, among which BMI1 (B lymphoma Mo-MLV insertion region 1
homolog; PCGF4), control cell proliferation in normal and oncogenic contexts [5,9,10]. Besides its
role in transcription and replication regulation, BMI1 is centrally positioned in DNA repair and its
overexpression has been correlated to resistance to tumor therapy [11,12]. Thus, PRCs function in
numerous DNA-templated processes, each with obvious importance for development, differentiation
and tissue homeostasis.
We previously showed that the PRC1 protein RNF2 (Ring Finger protein 2; RING1B; RING2)
controls cell proliferation during pre-HOX (E6-9) development via CDKN2A/P16INK4a [13], in
support of a cell-autonomous regulatory function of PRC1 in cell proliferation in post-implantation
development. In addition, BMI1-depletion has been correlated to stem cell maintenance defects, among
which in adult hematopoietic and adult peripheral and central nervous system (CNS) neural stem
cells [14–16]. The underlying cell biological aspects thereof are, however, currently not entirely
understood. Recent reports have also localized BMI1 to transit amplifying cell populations in
developing tissues [17,18]. During transit amplification (TA), lineage-committed descendants of
stem cells (progenitors) rapidly expand in numbers and simultaneously differentiate giving rise
to differentiated cell lineages. By inference, DNA transcription, replication and repair require tight
coordination during TA. Although recognized as an important transitional stage during which multiple
chromatin-based activities, virtually nothing is known about how TA is controlled at the molecular
level. Moreover, the biological relevance of BMI1 expression in the TA cell compartment is unknown.
Because of their functional versatility in regard to multiple chromatin-based processes, we
hypothesized that PRC1 proteins represent candidate regulators of TA. We recently established
that in the absence of the immediate early response gene EGR1, TA fails in a cell model for
chondrogenesis [19]. Relevantly, EGR1 displays regulatory interaction with PRC proteins at
multiple levels and EGR1-deficient cells show substantial reduction of BMI1 levels during the phase
corresponding to the early differentiation-associated proliferative burst [19]. Although presumed to
be involved in endochondral bone formation, a role for PRC1 proteins in chondrogenesis has not
been studied before. In the current study, we probed a potential regulatory involvement of PRC1,
in particular BMI1, during TA. To this end we focused on combining biologically relevant in vitro
and in vivo chondrogenic models for chondrogenesis. Our results show for the first time that TA is
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completely dependent on PRC1: using dynamic in-depth transcriptomic and epigenomic analyses
we prove that in the absence of functional PRC1, coordination of DNA-templated activities during
TA fails and results in massive DNA damage. Defective proliferation and differentiation early in TA
occur in the absence of major changes in global H3K27me3 marking. Instead, the inability to remove
Topoisomerase 2α cleavable-complexes in the absence of BMI1 provides a thus far unknown molecular
basis explaining for stalled replication and defective transcriptional control in PRC1-deficient cells.
2. Results
2.1. Loss of PRC1 Prevents Transit Amplification and Reduces Chondrogenic Capacity
The long bones of the mature ossified mammalian skeleton develop from a cartilaginous
scaffold via a process called endochondral ossification [20]. One of the most iconic examples of
a differentiation-associated amplifying (TA) cell population is the rapid expansion of chondrogenic
progenitors in the proliferative zone (PZ) of growing long bones (Figure 1A). Relevantly, numerous
PRC1-mutations have been linked to abnormal skeletogenesis in mice [6]. To probe for a
cell-autonomous role for PRC1 in TA, i.e., independent of Hox-associated A–P positioning, we used
murine ATDC5 cells, a well-defined in vitro model for chondrogenesis [21]. ATDC5 represent an early
mesenchymal progenitor cell type, which can be induced to undergo adipogenesis, osteogenesis or
chondrogenesis. Of note, ATDC5 differentiation encompasses both a transit amplification of progenitor
proliferation and chondrogenic transcriptional programming [21]. To assess their role in TA, we first
verified murine growth plates for the presence of PRC1 proteins with reported single or compound
mutant skeletal phenotypes [13,22–26]. PRC1 proteins BMI1, RNF2 and RING1 (RING1A) were clearly
expressed in the PZ/pre-HZ (pre-hypertrophic zone) of active growth plates in the murine femur
(Figure 1A). ATDC5 cells expressed and/or induced genes encoding PRC1 core-complex members
during chondrogenesis, among which pcgf genes (4/Bmi1, 2/Mel18) ring1 genes (i.a. Ring1A, 1B/Rnf2),
polyhomeotic-like (i.a. Phc1, 2), chromobox (i.a. Cbx2/M33, 4/Mpc2) and Rybp (Figure S1A). In line
with its prominent localization to the PZ/pre-HZ, BMI1 protein expression was markedly induced
in vitro at 6 days post-induction of differentiation (pid), suggesting an increased reliance of early
chondrogenic ATDC5 differentiation on PRC1 function (Figure 1B). We used a short hairpin (sh) vector
to reduce cellular BMI1; the shBmi1 vector efficiently reduced murine BMI1 levels at 6 days pid to
less than 50% of a control sh vector (shcon) levels (Figure 1B). BMI1-depletion impeded differentiation
as evidenced by altered Sox9 (biphasic chondrogenic marker) and Runx2 (late marker), collagen type
II, α1 (Col2A1) and aggrecan (Acan); Figure 1C and Figure S1B) and reduced chondrogenic nodule
formation in culture (data not shown; [21]). Conversely, over-expression of a murine Bmi1 (mBmi1)
cDNA enhanced expression of chondrogenic makers during differentiation (Figure S1C–E). The above
data is consistent with a role for BMI1 in chondrogenesis and validates the significance of the ATDC5
model to probe PRC1 function during TA.
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Figure 1. BMI1 is required for chondrogenic differentiation. (A) Histological sections of an active
murine femoral growth plate: (left panel) hematoxylin (hmtx) stained section (RZ: resting zone,
PZ: proliferation zone, HZ: hypertrophic zone, MZ: mineralization zone; m: marrow spaces);
immunohistochemical (IH) staining on growth plate sections (middle panels) for COL2A1 (collagen
type II; PZ marker), COL10A1 (collagen type X; HZ marker) and (right panels) for BMI1, RING1, RNF2;
IgG was used as negative control in IH; (B) Representative comparative immunoblot (IB) analysis
of BMI1 protein expression in ATDC5 cells stably expressing control (− shBmi1) or Bmi1 (+ shBmi1)
shRNAs at t = 6 days post induction of differentiation (pid; cc: non-differentiating conditions); bACT
loading control. Lower panel: quantification of BMI1 protein knock-down at t = 0, 6 and 10 days pid.
BMI1 proteins levels were normalized to beta-Actin (bACT) levels; asterisks (*): p < 0.05; (C) Expression
of chondrogenic markers Col2A1 and Acan mRNA in shcon vs. shBmi1 ATDC5 at indicted time-points pid
(RT-qPCR analysis); asterisks (*): p < 0.05. pid (post-induction of differentiation), cc (non-differentiating,
maintenance culturing conditions)
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We next examined the effect of BMI1-depletion on differentiation-associated TA using
RNAi-mediated knock-down. Under maintenance (i.e., non-differentiating) culturing conditions,
BMI1-depletion marginally affected cell proliferation rate (Figure 2A,B). Under chondrogenic
differentiation conditions BMI1-proficient control (shcon) ATDC5 cells underwent a phase of rapid
proliferative expansion (i.e., TA) between t = 1 to 6 days pid (Figure 2A) which coincided with the
observed BMI1 induction (cf. Figure 1B). In sharp contrast, BMI1-KD cells failed to undergo TA
under differentiation conditions: their proliferation rate did not exceed that of non-differentiating
(shcon or shBmi1) cells (Figure 2B). Reduced cell division in ATDC5 BMI1-KD cultures was confirmed
by near complete absence of cells positive for late-S and G2/M-associated H3S10-phosphorylation
(H3S10ph; Figure S2A). To obtain an objective, quantitative measurement for cell cycle progression,
BrdU-incorporation and DNA profiles were compared under maintenance (i.e., non-differentiation;
t = 0) and chondrogenic (i.e., differentiation; t = 6 days pid) conditions. At t = 0, no significant
differences in cell cycle phase-distribution or de novo DNA synthesis between control and BMI1-KD
cells were observed (Figure 2C and Figure S2B). In contrast, under differentiation conditions
(t = 6 days pid), BMI1-KD cultures, showed a more than two-fold higher percentage of cells in
S-phase (vs. shcon cells; Figure S2B); comparably low subG1 fractions under both conditions
suggested apoptosis did not contribute significantly to the observed differences (Figure S2B). S-phase
accumulation in shBmi1 cultures coincided with a dramatic reduction of BrdU-incorporation (i.e., de
novo DNA synthesis; Figure 2C). In methanol-fixed cells, brightness and subnuclear distribution of the
proliferating cell nuclear antigen (PCNA), a DNA clamp protein that acts as a DNA polymerase
(DPOL)-associated processivity factor, reflect commitment to DNA-synthesis (i.e., S-phase) and
S-phase progression, respectively [27]. As expected, most PCNA-bright shcon cells co-stained for
BrdU at t = 3 days pid and had thus committed to DNA replication (Figure S2C). In clear contrast,
numerous BMI1-deficient cells, although clearly positive for PCNA, had failed to incorporate BrdU
(Figure S2C). This combined data suggested that BMI1-depleted cells had undergone an intraS-phase
arrest. Similarly, primary human articular cartilage-derived (HAC) cultures exhibited coinciding
reduction of BrdU-incorporation and differentiation-associated proliferative capacity in the absence
of BMI1, independently confirming the TA-associated phenotype in PRC1-deficient cells (Figure 2D).
Comparable to BMI1-depletion, PHC2-depletion diminished chondrogenic proliferation and increased
S-phase accumulation (Figure S2D,E). Conversely, mBmi1-cDNA overexpression produced a modestly
but reproducibly enhanced TA phase (data not shown). The collective above data provides multiple
independent lines of evidence for a general involvement of PRC1 in chondrogenesis-associated
transit amplification.
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Figure 2. Loss of BMI1 elicits intraS-phase accumulation. Proliferation of shcon (A) and shBmi1 (B) 
ATDC5 cells under maintenance (cc) and differentiation (diff) conditions; dashed curves (B) represent 
the “shcon (diff)” and “shcon (cc)” curves in (A) as indicated in inset. Data based on three independent 
parallel experiments; asterisks (*; A,B): control versus differentiation conditions; p < 0.05; (**; B) “shcon 
(cc)” versus “shBmi1 (cc)”; p < 0.05. (C) Representative, corresponding experiments showing (C) de 
novo DNA replication at t = 0 and 6 days pid after 45 min (top & middle panels) and 6 h (bottom 
panels) BrdU-incorporation in shcon (left panels) and shBmi1 (right panels) ATDC5 cells. Numbers in 
bottom right corner of each panel indicates the % S-phase/BrdU-positive cells in these experiment; 
Figure 2. Cont.
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Figure 2. Loss of BMI1 elicits intraS-phase accumulation. Proliferation of shcon (A) and shBmi1 (B)
ATDC5 cells under maintenance (cc) and differentiation (diff ) conditions; dashed curves (B) represent
the “shcon (diff)” and “shcon (cc)” curves in (A) as indicated in inset. Data based on three independent
parallel experiments; asterisks (*; A,B): control versus differentiation conditions; p < 0.05; (**; B) “shcon
(cc)” versus “shBmi1 (cc)”; p < 0.05. (C) Representative, corresponding experiments showing (C) de
novo DNA replication at t = 0 and 6 days pid after 45 min (top & middle panels) and 6 h (bottom panels)
BrdU-incorporation in shcon (left panels) and shBmi1 (right panels) ATDC5 cells. Numbers in bottom
right corner of each panel indicates the % S-phase/BrdU-positive cells in these experiment; DNA
content was measured by propidium-iodide (PI) staining (quantitative representation: cf. Figure S2B);
white arrow marks BrdU-positive cells re-entering G1-phase; black arrows mark polyploid cells (shcon:
0.76% ±0.14; shBmi1: 3.46% ±0.25 at t = 6 days pid; p < 0.05) and (D) de novo DNA replication in
differentiating shcon and shBmi1 HAC cells and visualized by immunofluorescent (IF) detection of
BrdU-incorporation; representative IF images (upper panels) were deliberately selected based on areas
with near-equal cell density. Representative phase-contrast images (lower panels) reflect reduced
overall cell proliferation. Quantification of IF data is depicted to the right of the IF images (legend at
the bottom).
2.2. BMI1-Deficiency Leads to Increased Replication-Associated DNA Damage during Transit Amplification
IntraS-phase accumulation/arrest can be initiated as part of a DNA damage response (DDR) [28].
Stalled or damaged replication forks are known to coincide with double strand DNA breaks (DSB);
the latter are detectable by enhanced local Ser139-phosphorylation on histone H2A.X (yH2A.X) by
ATM, which signals DNA damage [29]. Combined, the intraS-phase arrest and coinciding diminished
de novo DNA replication of BMI1-depleted ATDC5 cells suggested that PRC1 function supports
differentiation-induced hyperproliferation through mechanism(s) that prevent intraS-phase checkpoint
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activation. To determine whether BMI1-depleted cells accumulate DNA damage during TA, nuclei
were analyzed for the presence of DSB using immunofluorescence (IF). Under maintenance conditions,
both control and shBmi1 ATDC5 cultures typically included some faintly yH2A.X-positive nuclei
(Figure S3A); although we cannot formally rule out any activity of other PIKK family kinases, it
is conceivable that the low yH2A.X signal related to normal local replication-associated DSB [30].
Increased DNA damage was observed in some experiments as early as t = 1 day pid in shBMi1 cultures
(vs. shcon; Figure S3B), whereas the yH2A.X signal had dramatically increased in BMI1-KD cultures at t
= 6 days pid (Figure 3A); at this stage, shBmi1 ATDC5 cultures had accrued approximately 3–4× higher
yH2A.X levels than differentiating shcon cultures (Figure 3B). DDR-mediated cell cycle arrest under
BMI1-depleted conditions was confirmed by very weak/absent H3S10ph-staining in nearly all (>95%)
brightly positive yH2A.X nuclei (Figure S3C). Single Cell Gel Electrophoresis (SCGE/comet) analysis
revealed significantly enhanced tail-moments in shBmi1 cultures (vs. shcon), independently confirming
the presence of DSB (Figure 3C). Increased ATM-induced KAP1S824-phosphorylation, enhanced
RAD51 and RPA70/chromatin-association in yH2A.X-positive nuclei during TA (Figure S3D–F) and
upregulation of DNA damage and repair pathways (Table S1) were consistent with the initiation of
DDR in BMI1-deficient cells. Similarly, also BMI1-depleted primary HAC cells showed elevated
yH2A.X levels at t = 2 days pid (Figure 3D and Figure S3G). Importantly, the above findings
provide definite evidence for enhanced DDR in BMI1-depleted cells in response to induction of
differentiation/proliferation and show that accumulation of DNA damage and intraS-phase arrest
coincide during chondrogenic TA in the absence of BMI1.
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Figure 3. Activation of DNA damage response (DDR) in the absence of PRC1. (A) Representative IF 
images of yH2A.X staining in ATDC5 shcon and shBmi1 cells at t = 6 days pid (upper panels); 
corresponding DAPI and phase-contrast images (middle and lower panels), showing nuclei and 
whole cells, respectively; scale bar: 10 µm. Quantification of immunofluorescence (IF) data is depicted 
below the IF images; 23% of shBmi1 cells displayed an enlarged flat cell phenotype; all enlarged cells 
were positive for yH2A.X; (B) Comparative IB analysis of total cellular histone modifications yH2A.X, 
H3K27me3 and H3K9me3 levels in shcon and shBmi1 cells at indicated time-points pid; (C) Double 
strand breaks (DSB) in differentiating shcon and shBmi1 cells were determined by SCGE assay (neutral 
comet assay); representative images of shBmi1 and shcon comets at t = 2 days pid (left panel); 
quantification of tail moments (right panel; Asterisk (*): p < 0.001); (D) Representative IF images 
showing yH2A.X staining in shcon and shBmi1 HAC (human articular chondrocytes) cells at t = 6 days 
pid (upper panels); corresponding DAPI images (lower panel). For quantification of IF data, see: 
Figure S3G. 
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Figure 3. Activation of DNA damage response (DDR) in the absence of PRC1. (A) Representative
IF images of yH2A.X staining in ATDC5 shcon and shBmi1 cells at t = 6 days pid (upper panels);
corresponding DAPI and phase-contrast images (middle and lower panels), showing nuclei and whole
cells, respectively; scale bar: 10 µm. Quantification of immunofluorescence (IF) data is depicted
below the IF images; 23% of shBmi1 cells displayed an enlarged flat cell phenotype; all enlarged cells
were positive for yH2A.X; (B) Comparative IB analysis of total cellular histone modifications yH2A.X,
H3K27me3 and H3K9me3 levels in shcon and shBmi1 cells at indicated time-points pid; (C) Double strand
breaks (DSB) in differentiating shcon and shBmi1 cells were determined by SCGE assay (neutral comet
assay); representative images of shBmi1 and shcon comets at t = 2 days pid (left panel); quantification
of tail moments (right panel; Asterisk (*): p < 0.001); (D) Representative IF images showing yH2A.X
staining in shcon and shBmi1 HAC (human articular chondrocytes) cells at t = 6 days pid (upper panels);
corresponding DAPI images (lower panel). For quantification of IF data, see: Figure S3G.
2.3. H3K27me3 Is not a Major Determinant of Transcriptional Repression during Differentiation
We next determined the effect of BMI1-depletion on global chondrogenic transcriptional
programming, by comparing gene expression profiles in control and BMI1-KD cultures between
successive time-points throughout differentiation. Whole transcriptome analysis in control cells
revealed that chondrogenesis-associated transcriptional programming became overt at t = 1 day pid:
beyond this time-point, loss of data-point clustering to the identity line indicated substantial change in
the overall gene expression profiles (Figure 4A). Importantly, this transcriptomic data independently
confirmed that differentiation-associated transcriptional programming coincided with TA. Of note,
beyond t = 6 days pid (i.e., days 6 to 15), chondrogenic profiles were stably maintained (Figure 4A). In
BMI1-KD cultures, data-point scattering between successive time-points was noticeable from t = 8 h pid
onwards, reflecting early transcriptional dysregulation in the absence of BMI1 (Figure 4A). Although
speculative, the observed restriction of transcriptome complexity at later time points (10 to 15 days)
pid in shcon cultures may relate to reduced proliferative capacity. When examined at the level of
individual genes, progressive differential gene expression between control and BMI1-KD cultures was
prominently visible between t = 1 and 6 days pid: over one-third of mRNAs was deregulated at least
1.2-fold in BMI1-KD cultures (Figure S4A). Of note, loss of BMI1 resulted in comparable percentages
up and down-regulated mRNAs (Figure S4B). Retrospective analysis of the most deregulated reporters
at t = 6 days pid revealed that misexpression of these reporters was already observed in BMI1-deficient
cultures early into differentiation, with genes mapping both to relevant and non-relevant pathways for
chondrogenesis (Table S2; Figure 4B). Independently, cluster analysis of more than two-fold deregulated
genes at t = 6 days pid, distinguished additional reporter sets that showed sustained transcriptional
repression in BMI1-deficient cultures throughout chondrogenic differentiation (Figure S4C,D). This
data supports the idea that loss of a transcriptional repressor (i.e., BMI1) did not exclusively induce
gene activity.
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Figure 4. Abnormal transcriptional responses in BMI1-deficient cells. (A) Matrix display of scatter-plots
of 2log expression values for all time-points relative to each other in shcon (upper right half) and shBmi1
cells (lower left half), based on reporters (i.e., mRNAs) fulfilling p < 0.05, absolute FC (fold change) ≥ 2,
expression > 2log(100) in either group, at t = 1 or 6 days pid. Perfect fit to the identity line (see: dashed
grey diagonal at the top of (A)) would indicate absence of differential expression between time-points).
Insets: (upper) t = 8 h vs. 1 day and (lower) t = 6 days vs. 15 days pid. (B) FC for all reporters. Box-plots
of shcon vs. shBmi1 log-ratios for all reporters (regardless of expression level, fold change or significance)
for each time point in differentiation; colors red or blue retrospectively mark genes with a ≥4 FC up
(red; n = 106) or down (blue; n = 49) at t = 6 days pid; box represents 1st–3rd quartiles; whiskers set at
1.5× interquartile distance.
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As PRC-mediated transcriptional regulation involves histone H3 lysine (K) 27 trimethylation
(H3K27me3), we examined global H3K27me3-marking in relation to transcriptional silencing
in shcon cells and whether this had changed in shBmi1 cells. Global H3K27me3 levels had
increased approximately two-fold in control cells by t = 6 days pid, whereas in BMI1-deficient
intraS-phase-arrested cells, chromatin-associated H3K27me3 had accumulated to substantially higher
levels; this increase paralleled enhanced levels the H3K27me3 methyltransferase EZH2 (cf. Figure 3B).
Also, H3K9me3 levels were higher in shBmi1 cultures at t = 6 days pid; the increase of both trimethyl
marks correlated with elevated yH2A. X during failed differentiation (cf. Figure 3B). To determine
whether aberrant transcriptional regulation correlated with abnormal Polycomb-associated histone
marking in BMI1-deficient cells, epigenome-wide H3K27me3-profiles of shcon and of shBmi1 cells were
compared at t = 0 and 3 days pid using chromatin-immunoprecipitation/deep-sequencing (ChIP-seq).
As demonstrated above, at 3 days pid, transcriptional reprogramming coincided with TA and DSB
featured prominently in shBmi1 cultures. We found that pre-chondrogenic H3K27me3-enrichment
(i.e., at t = 0 in shcon cells) within specified genic regions (i.e., promoter, TSS, gene-body) closely
correlated to low/absent transcriptional activity (Figure S5D), in keeping with published data in
various other systems [31–33]. Despite the substantial gene expression-reprogramming during normal
(shcon) chondrogenic TA, overall genic/intergenic H3K27me3-distribution remained largely unaltered
at t = 3 days pid (Figure S5E). Surprisingly, in BMI1-KD cultures, the overall correlation between
genic H3K27me3-marking and low/absent gene expression was sustained and relative genome-wide
H3K27me3-distribution did not significantly change, despite increased overall H3K27me3 levels
(Figure S5D,E). To probe for specific effects of BMI1-depletion on gene expression in relation to
changes in H3K27me3-marking, we analyzed gene expression changes during chondrogenic TA, at
loci that had gained or lost H3K27me3-decoration during early chondrogenic differentiation (i.e.,
t = 0 vs. 3 days pid), or that had remained stably decorated or non-decorated. Under normal
chondrogenic conditions (shcon) the range of fold-changed gene expression had increased in all
H3K27me3-marked and unmarked categories during chondrogenic TA (Figure S5F). In contrast, the
extent of fold-changed gene expression variation in BMI1-KD cells at 6 days pid was comparable to that
at t = 0, consistent with failed differentiation-associated transcriptome reprogramming (Figure S5F). Of
note: this occurred regardless of H3K27me3 marking, indicating that H3K27me3 per se is not a major
determinant of transcriptional repression during chondrogenesis and that the functional connection
between H3K27me3 and transcriptional regulation was lost in the absence of BMI1. Consistent with
its multidirectional effects on transcription deregulation (i.e., up and down-regulation; cf. Figure 4),
BMI1-depletion affected H3K27me3-marked and unmarked loci (reference: t = 0/shcon) alike during
chondrogenic TA (Figure 5A and Figure S5G). Expression profile analysis as a function of time
within two relevant gene networks representing chondrogenesis and cell proliferation (Tables S3
and S4), revealed that overall gene activity of these limited markers sets remained largely unaltered
between shcon and shBmi1 cells (Figure 5B and Figure S5H), irrespective of gain, loss or stable
H3K27me3-enrichment. The most prominent variation in gene expression in the ‘Cell cycle’ network
during TA (i.e., between t = 1 and 6 days pid), occurred among non-H3K27me3 enriched markers
(Figure S5H), consistent with checkpoint activation in the absence of BMI1. The above combined data
supports the notion that genic H3K27me3-marking alone is not sufficient for transcriptional repression
during differentiation and that the massive transcriptional deregulation in BMI1-deficient cells cannot
be solely explained by loss of PRC1-mediated transcriptional repression.
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Figure 5. H3K27me3-independent transcriptional deregulation in the absence of BMI1. (A) Altered
expression between t = 0 and 6 days pid is equally distributed over originally H3K27me3-enriched
and non-enriched genes (i.e., in BMI1-proficient shcon cultures at t = 0). Bar graphs show the number
of genes that are up- or down-regulated (above and below x-axis respectively) between t = 0 and 6
days pid, divided in H3K27me3-enriched and unmarked genes for three arbitrarily defined classes,
based on gene expression fold change (FC) between shBmi1 and shcon (FC > 1.1, 1.2 or 1.4, respectively).
Analyses was based on reporters with expression > log2(100). (B) Heatmap of representative marker
expression for ‘Endochondral ossification’ (cf. Table S3) for shcon (left panel) and shBmi1 (right panel)
ATDC5 cells. H3K27me3-enrichment status was defined based on ChIP-seq data comparison between
t = 0 and 3 days pid in the shcon experiment: unmarked (none), stably marked (stable) or loci that had
acquired (gain) or lost (loss) H3K27me3-marking (see Methods section for further definition of the
marker set H3K27me3).
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2.4. Abnormal TOP2A Cleavable-Complex Processing in PRC1-Deficient Cells Causes Double Strand
DNA Breaks
PRC1 is involved in at least three major DNA-templated processes relevant during differentiation
and TA: transcription, replication and repair, all of which are subject to dynamic chromatin structure
modulation. Topoisomerases are central to all three chromatin-based processes [34,35]. Relevantly,
PRC proteins were reported to reside in close proximity to the DNA-polymerase complex (DPOL)
during replication and to associate with topoisomerases and native DNA during S-phase in Drosophila
embryos and murine embryonic fibroblasts [36–38]. BMI1/RING1 was identified as a major E3-ligase
complex targeting topoisomerase 2 alpha (TOP2α) cleavable complexes in an siRNA-based screen
aimed at increasing toxicity of TOP2-directed drugs in cancer therapy [39]. The relevance of BMI1
as a potential TOP2α E3 ligase in a normal developmental biological context has, however, not been
established. Failure to undergo transcriptional reprogramming and TA in BMI1-depleted cultures
suggested defective coordination of multiple chromatin-based activities early during chondrogenesis.
Therefore, we next pursued the possibility that loss of nuclear coordination of transcription and
replication was the cause for DNA damage and DDR in BMI1-KD cells. To this end, we first
aimed to establish a functional interaction between PRC1 and TOP2α in ATDC5 cells. In good
agreement with the reported direct functional connection between BMI1/RING1 and TOP2α, we
found that loss or gain of BMI1 in ATDC5 cells increased or reduced sensitivity for the Topo-poison
etoposide, respectively (Figure S6A). Independently, PHC2 or RNF2-depletion reduced cell survival
in the presence of etoposide, pointing to a general involvement of intact PRC1 in controlling TOP2α
function (Figure S6A). DNA replication and transcription machineries both utilize topoisomerase
activity and hence introduce catalyzed DSB. Subsequent proteolytic removal of TOP2A-cleavable
complexes is required to expose and repair TOP2α-protected DSB as well as to ensure progression
of DNA and/or RNA synthesis [40]. Lack of a putative TOP2α-directed PRC1 E3-ligase activity
predicted an increased presence of covalently chromatin-bound TOP2α complexes during TA in the
chromatin-bound protein fraction of BMI1-deficient cells. Failure to detect any quantitative difference in
TOP2α-DNA intermediates at t = 0 (vs. shcon; Figure 5A) was in good agreement with the limited effect
of BMI1-depletion on proliferation in non-differentiating cultures (cf. Figure 2 and Figure S2). Whereas
in shcon cells total (soluble) cellular TOP2α was reduced under differentiating (vs. non-differentiating)
conditions, total TOP2α remained high in shBmi1 (vs. shcon) cells under differentiation conditions
(Figure 6A; cf. soluble fractions). Relevantly and in clear contrast to non-differentiated ATDC5
cells, TOP2α/chromatin-association was markedly increased in BMI1-depleted (vs. control) cells at
t = 6 days pid (Figure 6A). Increased presence of TOP2α predicted the presence of DSB at sites of de
novo DNA synthesis. Indeed, co-staining for newly incorporated BrdU and yH2A.X showed that all
BdrU-labeled nuclei were also positive for yH2A.X and, moreover, that nuclear foci of de novo DNA
synthesis overlapped perfectly with damaged DNA (Figure 6B). These collective chromatin-based
analyses are in good agreement with the reported PRC1 E3-ligase activity toward TOP2α and support
a biological role for this functional connection during chondrogenesis: failure to remove TOP2α in the
absence of PRC1 results in local DNA damage. The observation that expression of all three evaluated
PRC1 members is elevated under normal differentiating conditions in vivo and in vitro (cf. Figure S1A)
is congruent with the idea the chondrogenic TA phase requires PRC1.
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Figure 6. Abnormal coordination of DNA-templated activity in BMI1-depleted cells. (A) Detection of
covalently chromatin-bound topoisomerase 2 alpha (TOP2α) in the presence (− shBmi1) or absence
of BMI1 (+ shBmi1); duplicate shBmi1 (+) samples represent two independent parallel experiments;
to enable comparative quantitative assessment cytoplasmic and chromatin-bound fractions were
proportionally loaded; all samples were loaded on the same gel. Separation of chromatin-bound
(chrom) TOP2α fraction and soluble (sol; cyto + nucleoplasmic) TOP2α fractions was validated by
histone H3 and AKT detection, respectively; (t+) marks longer appositions; (B) Representative image
showing combined IF detection of local damage response (yH2A.X) and de novo DNA replication
(BrdU; 10 min BrdU pulse) in shBmi1 ATDC5 at t = 3 days pid; (C) Expression analysis (IB) of total
cellular POLR2A (tPOLR2A) versus phosphorylated POLR2A (pPOLR2A) in shcon and shBmi1 cells at
t = 0, 3 and 6 days pid. For quantification of protein levels, see Figure S6C; (D) Representative IF image
showing combined detection of phosphorylated POLR2A (pPOLR2A) and de novo DNA replication
(BrdU; 10 min BrdU pulse) in shBmi1 ATDC5 at t = 3 days pid; scale bar: 5 µm. For quantification of IF
data, see Figure S6E; (E) Cross-linking immunoprecipitation (XIP)-based assessment of colocalization
of pPOLR2A and PCNA with damaged DNA at t = 6 days pid. XIP was carried out using indicated
antisera on chromatin fractions of ±2000–5000 bp.
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2.5. Increased POLR2 Phosphorylation and Stalled Transcription Forks in BMI1-Depleted Cells
The enhanced presence of TOP2α on chromatin in BMI1-depleted cells during a period of
intense chromatin usage (i.e., combined chondrogenic transcriptional programming and increased
proliferation), is predicted to increase the risk of transcription forks and stalled replication forks
collision. Relevantly, PRC have been suggested to bind and disassemble RNA polymerase 2
holo-complex [41]. Accumulation of stalled transcription machineries, in turn, is expected to enhance
DSB and DDR during chondrogenic TA. We therefore set out to find evidence for transcription fork
stalling in BMI1-depleted cells. Transcriptional stalling is associated with hyperphosphorylation of
the largest subunit RPB1 of the RNA polymerase 2 holo-complex (pRPB1, henceforward referred
to as pPOLR2A) [42]. POLR2A hyperphosphorylation signals increased proteolytic removal of
arrested POLR2A complexes to bypass stalled transcription and repair transcription-associated DNA
breaks [43,44]. Phosphorylated POLR2A (pPOLR2A) had markedly increased between t = 0 and 3
days pid, both in shcon and in shBmi1 cells and pPOLR2A remained high throughout TA (Figure 6C).
The reduction of total POLR2A (tPOLR2A) in shBmi1 cells at t = 6 days pid significantly increased the
pPOLR2A/tPOLR2A ratio in BMI1-deficient nuclei (Figure 6C and Figure S6C). IF analysis revealed
that, although overall POLR2A phosphorylation was higher in shBmi1 than in shcon cultures, activation
of DDR (i.e., high levels of yH2A.X) correlated with severely reduced pPOLR2A detection at the
level of individual cells (Figure S6D), further strengthening the connection between DNA damage
and POLR2A degradation. To study a regulatory relationship between PRC1 and de novo DNA
replication and nuclear transcriptional activity, S-phase cells were allowed to incorporate BrdU and
were simultaneously stained for pPOLR2A. The majority of control cells displayed a seemingly
non-uniform nuclear distribution for active transcription at t = 3 days pid, whereas shBmi1 cells
consistently showed a high, mostly uniform staining for pPOLR2A (Figure 6D and Figure S6E). Closer
inspection of the IF images learned that especially the BrdU-bright shcon cells showed non-uniform very
weak pPOLR2A staining and, vice versa, that pPOLR2A-bright shcon cells were typically BrdU-dim
(Figure 6D and Figure S6E). In sharp contrast, this apparent inverse correlation between nuclear
pPOLR2A and BrdU staining was completely lost in BMI1-KD cells: all BrdU-bright cells were
pPOLR2A-bright as well (Figure 6D and Figure S6E). Conversely, not all shBmi1 PCNA-bright cells
had incorporated BrdU, consistent with intraS-phase arrest. Of note, BMI1-depleted cultures showed
substantially increased Geminin (GMNN)/chromatin association, a known PRC1 E3-ligase target
(Figure S6F) [45,46]. GMNN is involved in DNA replication and gene transcription, the latter
in concert with PRC1 [45,47,48]. The above combined data strongly corroborates the notion that
PRC1-mediated regulatory aspects of DNA transcription and de novo DNA replication are lost during
early chondrogenesis in the absence of BMI1.
Thus far our collective analyses suggested that loss of regulation of DNA replication and DNA
transcription in the absence of BMI1 may be related to increased replication and/or transcription
fork collision and stalling, resulting in DSB and enhanced DDR in S-phase cells during chondrogenic.
This idea predicted that replication machineries and transcription complexes may be positioned in
each other’s vicinity more frequently in BMI1-deficient cells and that this correlates with increased
DNA damage. To this end, we used an adapted chromatin cross-linking immunoprecipitation (X-IP)
approach that allowed examination of chromatin fragments spanning several thousand (2000–5000)
of base pairs; these chromatin fragments were analyzed for concurrence of PCNA (DNA replication
machinery), pPOLR2A (DNA transcription machinery) and DSB (yH2A.X) on such chromatin
fragments. Relevantly, PCNA IP co-precipitated pPOLR2A on chromatin fragments from BMI1-KD
extracts only (Figure 6E); both PCNA and pPOLR2A co-precipitated yH2A.X-positive chromatin, again
only in BMI1-KD cells only (Figure 6E). These findings support the notion that DNA damage results
from enhanced relative proximity and/or collision of replication and transcription machineries in the
absence of functional BMI1.
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2.6. BMI1 Prevents Premature Replication-Associated Senescence during Chondrogenesis
Several observations, including DDR and intraS-phase arrest, suggested that BMI1-depleted
ATDC5 cells may have undergone a senescence-like response (SLR) during defective TA/differentiation.
Consistent with SLR, BMI1 and RNF2-deficient cell cultures contained more cells displaying large/flat
cell morphology and increased polyploidy (Figure 2A, Figure 3A and Figure S7A). In addition, murine
ATDC5 and primary HAC cells showed increased nuclear H3K9me3 accumulation in the absence of
BMI1 (cf. Figure 3B and Figure S5B,C), an epigenomic feature associated with cellular senescence [49].
In further corroboration of SLR in BMI1-KD cultures, several SMS/SASP (senescence-messaging
secretome/senescence-associated secretory phenotype) indicators (e.g., Il-6, Ccl5, Cxcl10; [50,51])
showed an exaggerated response in the absence of BMI1 between t = 1 and 6 days pid (Figure S7B). Loss
of PRC1 function triggers premature senescence in several cultured cell types through transcriptional
activation of the Cdkn2a/Ink4a locus [10]. It is currently neither known whether premature senescence
features in (null)mutant PRC1-induced skeletal phenotypes nor whether Cdkn2a/Ink4a is implicated
at the molecular level. The finding that self-renewal of BMI1-deficient neuronal stem cells (NSC),
is dependent on Cdkn1a/p21Cip1/Waf11 instead of Cdkn2/Ink4a, supports the existence of multiple
lineage specific PRC-dependent control mechanisms in self-renewal and/or differentiation-associated
proliferation and is supported by other studies [5,52]. We first examined the ATDC5 model for an
involvement of Cdkn2a/Ink4a in SLR. Of relevance, important checkpoints, e.g., contact inhibition and
proliferative arrest after ionizing radiation, were found to be intact in non-differentiating ATDC5 [53];
(F.S. unpublished observations). Although expression profiles of several cell cycle inhibitors were
altered (e.g., Cdkn1b/p27Kip1, Cdkn2d/p19), the Cdkn2a/Ink4a expression profile remained unchanged
in BMI1-KD cultures compared to control cultures during chondrogenesis (Figure S7B), suggesting
Cdkn2/Ink4a may not be directly involved in the SLR reported here.
Endochondral differentiation terminates in chondrocyte hypertrophy in the hypertrophic zone
(HZ; cf. Figure 1A); here chondrocytes are replaced by invading osteoclasts and osteoblasts and
calcification of the extra-cellular matrix ultimately leads to the formation of calcified bone [20]. We
next explored the possibility that chondrocyte hypertrophy may represent an in vivo manifestation
of cellular senescence. Expression analysis of normal ATDC5 chondrogenic differentiation in vitro
revealed that numerous SMS markers were subject to dynamic regulation during TA (Figure S7B),
suggesting an analogy to SMS marker induction in the context of oncogene-induced senescence [50,51].
Senescent cells typically express the senescence-associated beta galactosidase 1 (SA-βGAL/GLB1)
protein [54]. Remarkably, induction of SA-βGAL activity was part of normal chondrogenesis in all
chondrogenic models we examined (Figure S7C–E). As the hypertrophic chondrocyte phenotype
may be causally linked to hyperproliferation in vivo, we reasoned that endochondral differentiation
terminates in a senescence-like condition and that SA-βGAL-positive cells should thus be detectable
adjacent to growth plates in elongating bones. Indeed, prominent SA-βGAL activity overlapping the
PZ/HZ was detected in growing murine long bones and in human and murine ribs (Figure 7A,B
and Figure S7F). Of note: SA-βGAL marked the proliferative and hypertrophic zones but not the
low-proliferative isogenic groups in human hyaline rib cartilage (Figure 7A); this finding further
supported a close association of enhanced cell proliferation and SA-βGAL-positive hypertrophy
during normal endochondral bone formation.
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Figure 7. Normal and premature senescence in chondrogenesis. (A) Active growth plates in human
ribs; combined alcian blue (alcBl; cartilage proteoglycan marker) and alizarin red (aznRD; calcified
bone marker) or SA-βGAL staining only (left panels); (right panels) IH-staining for COL2A1 and
COL10A1 (cf. Figure 1A); negative control: IgG. Hematoxylin (hmtx) image shown at left side.
PZ/HZ: proliferative/hypertrophic zones; IG: isogenous groups; m: marrow spaces. 30x magnification;
(B) SA-βGAL detection in growth plates of normal murine ribcages pp1 (postpartum day 1); (left panel)
combination staining of SA-βGAL and alizarin red (aznRd), (right panel) SA-βGAL staining only;
brackets mark PZ/HZ zones; (C) Quantitation of HZ-width measurements (left panel) in femurs of
Ring1−/− (homozygote genetic knock-out) versus Ring1+/− (heterozygote) and +/+ (wild type) pp1
mice. Asterisks indicate p-values: * p < 0.05; ** p < 0.001; (right panel) representative images of femur
growth plates of Ring1WT and Ring1KO pp7 mice (Sirius-red staining); brackets mark HZ.
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Numerous single PRC1 genetic null-mutant models display defective skeletogenesis and stunted
growth; some compound-PRC1 mutant mice reveal gross skeletal abnormalities including shortened
upper extremities [22–26]. Given the prominent PRC1 protein expression in growth plates (cf. Figure 1)
and the SLR induced by loss of PRC1 function in vitro, we predicted that SLR also occurs in vivo
and should become manifest as increased HZ-width in PRC1-deficient mice. To this end we probed
growth plates of newborn PRC1-mutant animals for the occurrence of premature senescence (i.e.,
increased numbers of hypertrophic cells). In keeping with this, homozygous Ring1 null-mutant (−/−)
newborn mice, which display a comparatively strong penetration of the PRC1 mutation-related skeletal
phenotype [26], revealed a significantly widened HZ compared to heterozygous (+/−; 19.8%) and
wild type animals (+/+; 34.0%; Figure 7C). These collective data support the notion that normal
endochondral bone formation incorporates replicative senescence during the late chondrogenic phase
and that PRC1 complexes play a pivotal role in preventing premature chondrogenic hypertrophy.
3. Discussion
In the current study, we establish a hitherto unknown involvement of BMI1 in chondrogenesis.
We define a crucial role for PRC1 during differentiation-associated TA and provide a detailed analysis
of the cellular and molecular consequences of PRC1 functional deficiency in TA chondrogenic
progenitors. In the absence of BMI1, cells fail to coordinate de novo DNA synthesis and active
DNA transcription during TA. We establish that failure to remove chromatin-bound TOP2α
complexes correlates with reduced DNA replication. Simultaneously, GMNN accumulation
correlates with hampered chondrogenic transcriptional programming, as evidenced by coinciding,
apparently non-H3K27me3-directed, transcriptional deregulation, hyperphosphorylation and
enhanced degradation of RPOL2A. Our collective data suggests that the absence of PRC1-E3 ligase
activity toward TOP2α results in massive accumulation of replication-associated DSB, which evokes
a DDR-induced intraS-phase cell cycle arrest. Ultimately, a replication damage-associated SLR
blocks functional chondrogenic progenitor expansion and differentiation. We present evidence that
programmed replicative senescence is an essential part of normal endochondral bone formation
and that DDR-induced SLR during chondrogenesis enhances hypertrophy during the formation of
long bones of a PRC1-mutant mouse and is likely to contribute to skeletal malformations. To the
best of our knowledge, the findings described herein for the first time provide a molecular basis for
PRC1-mediated coordination of multiple DNA-templated processes during TA in chondrogenesis and
position PRC1 as a ubiquitin E3 ligase for TOP2α in a relevant developmental context.
Our current and previous collective data suggests that H3K27me3 is not a primary determinant of
PRC1-mediated transcriptional repression. We have recently shown that transcriptional activity persists
during differentiation or physiological stress, despite increased genic H3K27me3-enrichment [33,55–57].
Conversely, PRC1 was suggested to be required for gene expression in specific settings [58–62],
illustrating the complexity of the functional interaction between PRC1 and H3K27me3 in the context
of transcriptional regulation. H3K27me3-decoration may provide local epigenetic marking that
directs lineage-dependent coordination of DNA transcription, replication. This notion is also in line
with recent observations that H3K27me3-marking correlates primarily with overall transcriptionally
repressed status prior to physiologically induced (i.e., differentiation, stress) transcriptomic changes
and that H3K27me3-marking hampers reprogramming within and between lineages [33,56,57,63–65].
Increased global histone H3K27 and H3K9 trimethylation in BMI1-deficient ATDC5 cells may be an
indicator of cellular/chromatin stress and concurrent protective responses rather than transcriptional
deregulation per se. We have recently shown that inhibition of the H3K27-demethylase JMJD3
under low oxygen conditions is responsible for epigenome-wide enhanced H3K27me3 [33,57]. As
chondrogenesis prominently features proliferation and differentiation under hypoxic conditions and
JMJD3 was reported to promote proliferation and hypertrophy during chondrogenesis [66], a regulatory
involvement of histone trimethylation by JMJD3 would appear plausible. Increased methylation at
H3K9, H3K27 and H4K20 have been correlated with cell-cycle exit and cell death [67,68]. In keeping
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with this idea, we recently reported abnormal global trimethylation at H3K4, K9 and K27 in the context
of defective TA in chondrogenic differentiation [19]. We currently have no definitive explanation for
the decline of H3-associated trimethyl-marks at later stages in development. Although mRNA levels
of the corresponding epigenetic effector PRC2 complex members EZH2, EED, SUZ12 (H3K27me3)
and SUZ39H2, SETD1 proteins (H3K9me3) decreased toward later stages of differentiation (cf. Figure
S1A), it is unclear whether and how these Lysine methyl transferases (KMT) and/or their functional
demethylating counterparts (KDM) are involved in late chondrogenic epigenomic changes. Whereas
senescence has been associated with enhanced nuclear H3K9me3 (also see below) [49], whether and
how increased global H3K27me3 is also connected to cellular senescence is less clear at this time.
BMI1/RING1 were identified as an important E3-ligase complex targeting TOP2α for
ubiquitin-mediated degradation in a siRNA-based screen for increased toxicity of TOP2-directed
drugs: in the absence of functional PRC1, TOP2α cleavable complexes accumulate on chromatin,
which has obvious relevance for cancer therapy, as it increases sensitivity for Topo-directed drugs [39].
We here establish that, besides RING1 and BMI1, RNF2 and PHC2 are also crucial partners in the
functional interaction between PRC1 and TOP2α. We here define for the first time a functional
significance for this biochemical relationship in a relevant development context. Our analyses point
to transcriptional deregulation during TA in the absence of functional PRC1, rather than a simple
failure to repress specific PRC1 targets in defined differentiation routes. We propose a model in which
PRC1, via its Ubiquitin E3-ligase activity, functionally connects DNA replication, transcription and
repair via several regulatory nodes associated with chromatin. This idea is good agreement with
the observations that PRC2 complexes are localized to replication forks and control progression and
symmetry of DNA replication forks ([38,69]. Among potential candidate partners for such a regulatory
liaison is GMNN. GMNN is involved in lineage commitment and differentiation through mechanisms
involving Polycomb Group proteins and prevents re-replication at the end of S-phase; in addition,
GMNN and PRC1 co-regulate gene transcription [45,47,48]. Loss of PRC1 E3-ligase function was
shown to stabilize GMNN, which interferes with haematopoietic stem cell self-renewal [46]. Dynamic
segregation of mRNA and DNA synthesis is known to occur throughout S-phase, as proximity of
transcription and replication forks increases the risk of fork collisions and DNA damage. We observed
an increase in yH2AX phosphorylation that coincided in space and time with sites of active DNA
replication during transit chondrogenic proliferative amplification. Although we cannot formally
rule out an involvement of additional PIKK-family kinases in the phosphorylation of histone variant
H2A.X and the resolution thereof at later differentiation stages, based on the evidence provided
herein, we interpret the enhanced DSB as the outcome of increased replication stress, in coherence
with a recent report on the effect of loss of PRC2 function [38]. It is conceivable that in part the DNA
damage results from failure to remove covalently bound TOP2A cleavage complexes. Spatio-temporal
coordination of replication and transcription is re-defined during differentiation [70–72]. Of note, this
occurs in midS-phase, a period during which we and others have observed dynamic regulation of
PRC1-chromatin association involving PRC1 phosphorylation [73]. As PRC complexes were shown to
remain associated with chromatin during DNA replication [36,69,74], this ideally positions PRC1 to
locally tune transcription to replication activity. Of relevance, PRC1-proteins were shown to occupy
promoters of actively transcribed genes and are required for POLR2A complex disassembly [41,75]. We
recently showed transcriptional activation of the immediate early gene ATF3 in response to mitogenic
signaling, involves release of chromatin-bound PRC1-complex members without the need for local
change in promoter H3K27me3-marking [55]. PRC1-mediated transcriptional repression, instead,
appears to be dependent on ubiquitylation of H2AK119, which is also involved in DNA repair [76–78].
It is conceivable that PRC1-dependent E3 ligase activity toward specific targets, e.g., H2AK119, GMNN
and/or TOP2A and PRC1 complex composition are locally controlled by specific post-translational
modification [79–81]. It is thus tempting to speculate that the PRC1-GMNN partnership represents
a molecular choice mechanism between DNA replication (GMNN absent) and RNA synthesis
(GMNN present) which, via H3K27me3-directed positioning of PRC1 complexes, plays a vital role in
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lineage-dependent spatio-temporal control of transcription and replication during development. In
this light, a comparative study on effects of PRC2-depletion on replication and transcription timing
in embryonic stem cells and neuronal progenitors revealed premature expression of lineage-specific
genes [82]. The chondrogenic model, which incorporates both PRC1-mediated proliferative and
transcriptional reprogramming during mesenchymal lineage-commitment, encompasses the required
dynamics to study replication and transcription timing in the context of PRC1 function.
Our collective findings reported in this study support a thus far unrecognized cell-autonomous
role for BMI1/PRC1 in proliferative and transcriptional control during endochondral bone formation.
The resulting cell cycle arrest and premature senescence-like hypertrophy is expected to contribute
to abnormal formation, development and growth of the skeletal elements in PRC1-mutant animals,
in addition to abnormal A–P positioning due to defective establishment and/or maintenance of
Hox-gene expression boundaries [4,6]. We here report that chondrogenic hypertrophy shares multiple
cellular and molecular characteristics with replication-stress induced senescence. Chondrocytes
harbor a remarkable ability to hyper-proliferate under conditions unfavorable for cell division (e.g.,
cartilage is avascular and hypoxic) [83]. Interestingly, a recent report showed that PRC-mediated
gene regulation of the checkpoint involving CDKN2A/P16INK4A is dependent on the physiological
oxygen levels [38]. Given that chondrogenic cultures rapidly become confluent and multi-layered
and thus likely hypoxic, this may explain the apparent insensitivity of transcriptional activity at the
Cdkn2a locus to BMI1-depletion. In addition, chondrogenesis greatly relies on enhanced endoplasmic
reticulum-stress signaling (ERSS) and unfolded protein response (UPR) [84,85]. Both ERSS and
UPR are known inducers of oncogene-induced senescence (OIS) [86]. Hyperproliferation-associated
replication damage and senescence are important features of OIS and suggest functional analogy
with chondrogenic hyperproliferation/hypertrophy. A biological analogy between chondrocyte
hypertrophy and programmed cellular senescence is also consistent with the role for RUNX
proteins both in endochondral ossification and in OIS [87,88]. Of note, BMI1 rescues oncogenic
H-RASV12-associated OIS and thereby cooperates with RAS in oncogenesis [89]. Hence, enhanced
BMI1 expression during chondrogenic TA shares important molecular characteristics with cellular
responses to oncogenic activation and emphasizes a pivotal role for PRC1 in facilitating DNA
replication under conditions of enhanced chromatin remodeling.
BMI1 is regarded as a stem cell marker, as ablation of PRC1 function is associated with depletion
of stem cell compartments due to defective self-renewal [14–16]. A mechanistic, cell biological
explanation for compromised stem cell self-renewal capacity in the context of PRC1-deficiency,
however, remained unclear. PRC and stem cell transcription factors (SCTF) like Nanog, are known
to co-occupy key developmental regulators genes in embryonic stem cells (ESCs) and SCTFs are
PRC-targets themselves [90–93]. Of relevance, instead of a typical TP53-dependent DDR and apoptosis
in response to DSB, ESCs accumulate TP53 at the promoter of the gene encoding the stem cell
transcription factor Nanog which leads to down-regulation of Nanog expression [94]. Integrity of
the stem cell compartment is thus maintained by elimination of damaged ESCs via induction of
differentiation. In light of our findings, it is conceivable that replication-mediated DNA damage and
induced abnormal differentiation may contribute to loss of self-renewal in PRC1-deficient totipotent
stem cells.
The collective findings presented in this study show that defective coordination of DNA and
RNA synthesis during chondrogenic TA in the absence of functional PRC1, is a major source of
replication stress, encompassing DNA damage, DDR and SLR. Our observations suggest a central
regulatory role for PRC1 at the cross-roads of DNA transcription, replication and repair in transit
amplifying progenitor cells, in line with an important role for PRC1 in replication-associated chromatin
damage-avoidance. These findings have important implications for the mechanistic understanding of
PRC1 proteins in stem cell biology, in embryogenesis and regenerative applications and in oncogenesis
and are expected provide new leads for further study.
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4. Methods
4.1. Cell Culture, Differentiation Assays
Differentiating ATDC5 cultures become multi-layered and develop distinctive three-dimensional
nodules that produce cartilage matrix proteins [21]. ATDC5 differentiation is monitored by sequential
chondrogenic marker gene expression (e.g., Sox9, Runx2, Col2A1, PZ; Acan and Col10A1, HZ;
Figure 1A) [20]. Culture conditions chondrogenic cells (ATDC5, HAC, kper): 37 ◦C, 5% CO2, 100%
humidity; DMEM/F-12, 5% FCS (supplements: Penicillin/Streptomycin, L-Glutamin). Human
U2-OS osteosarcoma or SW1353 cells chondrosarcoma were maintained in DMEM, or DMEM/F12,
respectively, supplemented with 10% FCS. HAC from a single donor were obtained from the unaffected
regions of osteoarthritic (OA) cartilage from total knee arthroplasty (Medical Ethical Committee
(MEC) approval 08-4-028). Rabbit-derived chondrogenic cells (COP, kper) were obtained as surplus
surgical material in non-related procedures (Animal Ethical Committee (DEC) approval 2005-159). For
differentiation experiments (6400 cells/cm2, overnight attached) ITS differentiation medium (10 µg/mL
Insulin, 10 µg/mL Transferrin, 3 × 10−8 M Sodium Selenite) was used for all cells. De novo DNA
replication: cells were incubated with BrdU (100 nM/mL) for the indicates timespan. Etoposide was
added for 30 min; cells were then washed and grown for an additional 9 days.
4.2. Retroviral Vectors, Infections
Retroviral systems and Phoenix helper-free retrovirus producer cell lines were used as published
before [95,96]. Ecotropic retroviral supernatants were produced by transfection of producer cells with
calcium-phosphate precipitation; 24–48 h post-transfection, the supernatant was harvested, filtered
and used for transduction of ATDC5, HAC or U2-OS cells in presence of 4 µg/mL polybrene. For
transduction, cells were incubated with viral suspensions for 12 h and allowed to recover for 24 h on
fresh medium before selection pressure was applied. Transduced cells were selected with puromycin
(8 µg/mL) for 72 h, before experiments were initiated; at the onset of experiments the puromycin
concentration was lowered to 2 µg/mL for the duration of the experiment. shRNAi vectors were
based on the pRetrosuper system (courtesy R. Agami, Amsterdam, The Netherlands) [97]. Efficacy of
shRNAi vectors was verified in U2-OS cells expressing tagged target proteins (Bmi1-2PY, HA-Rnf2,
HA-Phc2). The human + murine shBmi1[h + m] vector targeted human BMI1 and efficiently reduced
recombinant and cellular murine BMI1 levels. shGFP (courtesy A. Goodarzi, Calgary, Canada) was
used as reference shRNAi (shcon) throughout these studies [98]. Target sequences used:
shBmi1[m + h] (ENSMUSG00000028796): 5′-GTTCACAAGACCAGACCAC-3′,
shRnf2[m] (ENSMUSG00000028796): 5′-GTATCTGGCTGTGAGGTTA-3′,
shPhc2[m] (ENSMUSG00000028796): 5′-GTTCAAGCGTTCCAAGCGC-3′.
4.3. Proliferation Assays
ATDC5 cells were plated in 12-multiwell plates (Greiner Bio-One B.V, Alphen aan de Rijn,
The Netherlands). At each time point cells were washed twice with phosphate-buffered saline and
fixed for 10 min with 3.7% formaldehyde at room temperature. Next, cells were rinsed 5 times with
demineralized water. Cells were stained with 0.1% Chrystal violet for 30 min or overnight and washed
5 times with demineralized water. Chrystal violet was extracted with 10% acetic acid and absorbance
was measured spectrophotometrically at 590 nm (Benchmark, Biorad, München, Germany).
4.4. Immunoblot Analysis
Cells were lysed in RIPA buffer containing 5 mM Benzamidine, 5 µg/mL Antipain, 5 µg/mL
Leupeptin, 5 µg/mL Aprotinin, 1 mM Sodium Vanadate, 10 mM Sodium Fluoride, 10 mM
Pyrophosphate, 10 mM β-Glycerophosphate, 0.5 mM DTT and 1 mM PMSF. Lysates were subjected to
3 freeze-thaw cycles in liquid nitrogen and to 3 cycles of sonication. After centrifugation for 10 min
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at 13.2k rpm, protein concentration was determined using a BCA protein assay kit (Pierce). Equal
amounts of protein were boiled in Laemmli buffer and loaded on 9–15% Polyacrylamide gels. Proteins
were transferred to Polyinylidene Fluoride (PVDF) membranes. After blocking with 5% non-fat
dry milk in PBS containing 0.1% Tween-20, membranes were incubated o/n at 4 ◦C with primary
antibodies. After extensive washing, membranes were incubated with corresponding horseradish
Peroxidase conjugated secondary antibodies for 1 h at room temperature. Signals were detected using
enhanced chemoluminescence. Quantitative analysis was carried out using Chemi Luminescent Image
capture software (Chemidoc XRS, Biorad, München, Germany). Cell fractionation assays were carried
out as described before: quantitative comparison between different fractions was enabled by loading
volume equivalents [55].
4.5. Immunofluorescence
Briefly, cells were washed and fixed for 10–15 min in 100% Methanol at −20 ◦C and stored
at 4 ◦C in 70% Ethanol or used directly for immunocytochemistry. Cells were permeabilized for
5–10 min in 0.2 & Triton-X in PBS. To prevent epitope loss in combination with acid treatment for BrdU
detection, primary antisera were incubated for 1.5 h at 37 ◦C, 4–5× washed in 0.02% triton-X/PBS
and fixed in 2% Formaldehyde/PBS for 10 min at room temperature. Cells were washed with PBS
and incubated for 20 min in 2.0 N HCl at 37 ◦C, followed by two rinses of 0.1 M Sodium Tetraborate
solution, pH 8.5 for in total 2 min. Cells were than incubated with the primary antisera against
BrdU, washed at indicated before and incubated with secondary fluorescently labeled antibodies.
All antisera were diluted and incubated in 0.02% Triton-X in PBS. Nuclei were counterstained with
4′-6-Diamidino-2-Phenylindole (DAPI) and washed in 0.02% Triton-X/PBS. The last wash step was
in PBS, upon which cells were dehydrated: 1 min in 70% Ethanol, 2× 1 min in 100% Ethanol and
air-dried and mounted in Vectashield (Vector Laboratories, Inc. Burlingame, CA, USA). Parallel images
of shcon and shBmi1 cells were acquired using identical exposure times at identical magnification
throughout this study and were analyzed using a NIKON TE200 Eclipse fluorescence microscope and
photographed using a NIKON DXM1200 digital camera in combination with NIS Elements 3.0 Imaging
software (Nikon Instruments Europe B.V., Amsterdam, The Netherlands). For quantification of IF
images, at least 100 randomly selected cells (based on DAPI or phase contrast image) were counted
per genotype (i.e., shcon, shBmi1); IF-positivity, as indicated in (supplemental) figures or figure legends,
was expressed as a percentage of total number of counted cells.
4.6. Antibodies
Anti-β-ACTIN (C4, 691001, MP Biomedicals, Eschwege, Germany), anti-GAPDH, anti-H3K27me3
(#07-449), anti-H3K9me3 (#07-442), anti-H3S10Ph (#06-570), anti-γH2A.X (JBW301), anti-PCNA
(PC10) (EMD Millipore, Amsterdam, The Netherlands, ,anti-yH2A.X (Ser139; #2577) (Cell signaling),
anti-BrdU (BD Biosciences, Leiden, The Netherlands), anti-EZH2 (courtesy D. Pasini; Copenhagen,
Denmark), anti BMI1(F6) (courtesy M.vLohuizen, Amsterdam, The Netherlands), anti-PHC2 and
anti-RNF2 (courtesy of H.Koseki, Chiba, Japan [99]), anti-RING1 (courtesy A.Otten, Amsterdam,
The Netherlands [100]), anti-GMNN (sc-13015), anti-RAD51 (sc-8349; Santa Cruz, CA, USA),
anti-pKAP1 (S824) A300-767A (Bethyl Laboratories, Montgomery, TX, USA), anti-COL2A1 II-II6B3
(Hybridoma bank, Iowa city, IA, USA), anti-COL10A1 (courtesy G.P.Lunstrum, Portland, OR,
USA), anti-BMI1 (ab38432), anti-POLR2A (ab817), anti-pPOLR2A II (ab24759), anti-RPA70 (ab12320),
anti-TOP2A (ab73724; Abcam, Cambridge, UK).
4.7. Single Cell Gel Electrophoresis Assay (Neutral Comet Assay)
Suspended cells (0.5% of low melting point agarose/PBS, 37 ◦C) were dispersed on microscope
coated slides (1.5% agarose). Slides were lysed (overnight, 4 ◦C; 2.5 M NaCl, 100 mM EDTA, 10 mM
Tris, 250 mM NaOH, 1% Sodium Lauryl Sarcosinate, 10% DMSO and 1% Triton X-100, pH 10), subjected
to electrophoresis (20 min, 25 V, 300 mA, 4 ◦C), fixed (100% ethanol) and stained (20 µg/mL Ethidium
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Bromide). A minimum of 100 nuclei was scored per sample, per time point (Comet assay III software;
Perceptive Instruments, Haverhill, UK). Mean Comet tail moments were used to assess DSB in triplicate
assays; statistical analyses: two-sided, non-paired t-testing.
4.8. RNA Isolation, cDNA Synthesis, Quantitative PCR Analysis
For quantitative PCR (qPCR) analysis, total RNA from three independent parallel experiments
was isolated using Tri-Reagent (Sigma) according to the manufacturers’ protocol. Quantity and quality
of the RNA were determined by 260/280 nm and 260/230 nm absorbance measurements, respectively,
using the Nanodrop (Witec AG, Luzern, Switzerland). Total RNA (1 µg) for each sample/replicate
was converted into first strand cDNA using the iScript™ cDNA synthesis kit (Bio-Rad, Herculus, CA,
USA) according to the manufacturers’ instructions. Gene expression was determined by real-time
qPCR using the MyiQ™ Thermal Cycler (Bio-Rad) in combination with the IQ5 v2 software (Bio-Rad).
qPCR was performed on 25 ng of cDNA using the qPCR iQ™ Custom SYBR® Green Supermix with
fluorescein (Bio-Rad) and 300 nM primer in 96 well plates (Bio-Rad). For each primer pair a standard
curve was generated with a serial dilution of a cDNA pool. qPCR data was analyzed according to the
relative standard curve method. All values were normalized to Cyclophillin A. The control conditions
were used as a reference. Primer sets for the selected genes were developed with Primer Express
version 2.0 (Applied Biosystems, Foster City, CA, USA) using default settings (see below).
4.9. Affymetrix Expression Arrays, Pathway Analysis
For gene expression arrays, three independent replicate RNA samples were taken at each time
point during differentiation (0, 2, 4, 8 h, 1, 6, 10 and 15 days) from shcon and shBmi1 cultures. Total RNA
was isolated using the RNeasy kit (Qiagen, Venlo, The Netherlands) according to the manufacturers’
protocol. The isolated RNA samples were processed by ServiceXS BV (Leiden, The Netherlands)
according to Affymetrix (Santa Clara, CA, USA) protocols. In brief, RNA concentration was measured
by absorbency at 260 nm using the Nanodrop (Nanodrop Technologies, Wilmington, DE, USA)
and RNA quality and integrity was verified by using the RNA 6000 Nano assay on the Agilent
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). For each sample 2 µg high quality
total RNA was labeled using the Affymetrix Eukaryotic One-Cycle Target Labeling and Control
reagents to generate Biotin-labeled cRNA. The quality of the cRNA was verified using the Agilent
2100 bioanalyzer and the concentration was measured using the Nanodrop (Nanodrop Technologies,
Wilmington, DE, USA). Labeled cRNA was used for hybridization to 48 custom Affymetrix NuGO
Mouse GeneChip arrays (NuGO_Mm1a520177). After an automated process of washing and staining,
absolute values of expression were calculated from the scanned array using the Affymetrix GCOS
software. Data preprocessing and analysis was conducted based on scripts from ArrayAnalysis.org
using R2.7.1 [101] and Bioconductor libraries (http://www.R-project.org) [102]. Data were 2log
transformed and normalized (gcRMA) [103]. Probe annotations were updated using the Ensembl
based Brainarray annotation file [104]. Statistics computation for each reporter on the arrays included:
the average (2logged) expression of each group, the logratio (2log fold change) between the two
groups and the t- and p-value of a Student t-test, all for each time point. Subsets of reporters fulfilling
specific criteria were selected for various analyses, where generally cut-offs on p-value, logratio
and minimum expression (p < 0.05, absolute FC (fold change) ≥ 2, expression > 2log(100) in either
group, at any time point) were imposed and controls removed from the data set. For pathway Z
score analysis, expression at any given time point was compared between the respective genotype
and referenced to t = 0; overall shBmi1/t = 0 expression signal was normalized against shcon/t = 0.
Unless otherwise specified (Figure legends), cut-off limits had to be met at either t = 1 or 6 days
pid. GenMAPP was used for biological process annotation [105]. Overrepresentation of biological
processes was determined using PathVisio (http://www.pathvisio.org) using pathways available
through WikiPathways (www.wikipathways.org) [106].
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4.10. H3k27me3 Chip-Seq, Data Processing: Alignment, Normalization, Background Correction, Identification
of Enriched Regions
Cells were disrupted by sonication, yielding genomic DNA fragments ranging from 200–1000 bp,
with a bulk size of 200–500 bp. For each immunoprecipitation 10–20 million cells were used. 1% of the
cell suspension was kept aside as input DNA to use as a reference. Chromatin immunoprecipitation
(ChIP) was performed and analyzed as described before with minor adjustments [93]. ChIP-grade
H3K27me3 antiserum: 07-449 (Upstate). Immunoprecipitated DNA was checked for enrichment using
real-time PCR and quantified by fluorescence detection using Quant-iT™ Picogreen® dsDNA Reagent
(Molecular Probers/Invitrogen, Eugene, OR, USA) before deep sequencing was applied. Input and
ChIP samples were further processed and sequenced using the Illumina next generation sequencing
platform as described [107].
Image processing and base calling was performed using Illumina software tools provided by
the manufacturer. Subsequent genome alignment was performed using Bowtie with Mouse Genome
Build 9 (MM9) used as a reference genome, keeping uniquely aligned reads only for further analysis.
To remove PCR artifacts, all data were collapsed prior to peak calling. H3K27me3 data sets were
normalized based on genes with stable H3K27me3-enrichment (>0) in shcon and shBmi1 samples at
both 0 and 3 h pid; the cumulative area under the curve for all peaks within these regions was scaled
relative to the smallest value among the samples. H3K27me3-marking at the HoxA cluster, which
harbors both PRC1-target (i.a. HoxA9-13) and non-target loci (i.a. HoxA1-4) [19] was used to exemplify
stable H3K27me3-enrichment at t = 0 and t = 3 days pid (Figure S8A,B). The H3K27me3 enrichment
level, i.e., peak height, associated with stably and actively transcribed genes was used as a cut-off for all
samples. The reasoning is that such genes should have no or very low levels of H3K27me3 enrichment.
Stably and actively transcribed genes were defined as having a minimum expression larger than 99th
percentile of the minimum expression values of all genes across (i) shcon and shBmi1 and across (ii) all
time-points for which gene expression data was available. The cut-off corresponds to an estimated
H3K27me3 enrichment FDR of 1%, i.e., the proportion of genes classified as H3K27me3-marked while
the intensity of these markings is within background level is expected to be equal or less than 1%.
Signal intensities below this cut-off were not considered biologically relevant. To identify enriched
regions in the ChIP samples, the peak caller Findpeaks (version 4.0) was used with settings adjusted
to detect blanketing enrichment (a well-known problem for H3K27me3 enrichment finding), next to
sharply defined peaks.
4.11. H3K27me3-Enrichment Data Summarization, Integration Gene Expression Data
To quantify enrichment, each gene was divided into three regions: the promoter region
(−3000/−100 base pairs (bp) in relation to the TSS), the TSS region (−100/1000 bp), the gene body
region (+1000 bp to the end of the last exon). The total area under the curve for each region was
calculated and log10 transformed. Based on these quantifications, 2-fold changes in either direction
were considered as substantial changes in H3K27me3-enrichment, while fold changes smaller than 0.5
were considered a sign of stable H3K27me3-enrichment. Genes with enrichment changes between 0.5
and 2 were not considered for differential occupation analyses. Only genes for which both expression
data (see above) as well as H3K27me3-enrichment data (enrichment≥ 0) was available were considered
for further analysis (16261 genes in total). For the identification of enriched genes, we defined a gene
as the region between its 5′ (most upstream TSS) and 3′ (last exon) end plus 5 kb regulatory regions up
and downstream respectively. A gene was called marked when there was a peak present within this
region as determined by the enrichment finding procedure outlined above.
4.12. Cross-Link Immunoprecipitation (X-IP), Deep-Sequencing, Chromatin-Association Studies
Briefly, ATDC5 cells were fixed in 1% formaldehyde. Cross-linking was allowed to proceed for
10 min at room temperature and stopped by addition of glycine at a final concentration of 0.125 M,
followed by an additional incubation for 5 min. Fixed cells were washed twice with PBS and harvested
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in SDS Buffer (50 mM Tris at pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA), supplemented with
protease inhibitors (Aprotinin, Antipain and Leupeptin all at 5 µg/mL and 1 mM PMSF). Cells were
pelleted by centrifugation and suspended in IP Buffer (100 mM Tris at pH 8.6, 100 mM NaCl, 0.3% SDS,
1.7% Triton X-100 and 5 mM EDTA), containing protease inhibitors. Cells were disrupted by sonication,
yielding genomic DNA fragments with a bulk size of 200–500 bp. For each immunoprecipitation,
1 mL of lysate was precleared by addition of 35 µL of blocked protein A beads (50% slurry protein
A-Sepharose (Amersham/Sigma-Aldrich, Zwijndrecht, The Netherlands); 0.5 mg/mL fatty acid-free
BSA, Sigma; and 0.2 mg/mL herring sperm DNA in TE), followed by clarification by centrifugation.
10 µL aliquots of pre-cleared suspension were reserved as input DNA and kept at 4 ◦C. Samples were
immunoprecipitated overnight at 4 ◦C with antibodies for H3K27me3 (07-449; Upstate). Immune
complexes were recovered by adding 40 µL of blocked protein A beads and incubated for 4 h at 4 ◦C.
Beads were washed three times in 1 mL of mixed micelle buffer (20 mM Tris at pH 8.1, 150 mM NaCl,
5 mM EDTA, 5% w/v sucrose, 1% Triton X-100 and 0.2% SDS), twice in 1 mL of Buffer 500 (50 mM
HEPES at pH 7.5, 0.1% w/v Deoxycholic Acid, 1% Triton X-100 and 1 mM EDTA), twice in 1 mL of LiCl
Detergent wash buffer (10 mM Tris at pH 8.0, 0.5% Deoxycholic Acid, 0.5% NP-40, 250 mM LiCl and 1
mM EDTA) and once in 1 mL of TE. Immuno-complexes were eluted from beads in 250 µL elution
buffer (1% SDS; and 0.1 M NaHCO3) for 2 h at 65 ◦C with continuous shaking at 1000 rpm and after
centrifugation supernatants were collected. 250 µL elution buffer was added to input DNA samples
and these were processed in parallel with eluted samples. Crosslinks were reversed overnight at 65 ◦C
followed by a 2 h digestion with RNAse A at 37 ◦C and 2 hrs proteinase K (0.2 µg/µL) at 55 ◦C. DNA
fragments were recovered using QIAquick PCR purification columns, according to manufacturers’
instructions. Samples were eluted in 75 µL EB buffer and then further 1/5 diluted in TE buffer.
To assess relative proximity of replication and transcription machineries, cross-linked chromatin
(10 min, 1% formaldehyde, room temp) was sheared to a fragment size range of ±3000–5000 bp and
used for reciprocal IPs. Equal chromatin-input in IPs was assessed by DNA concentration measurement.
For TOP2A/chromatin-association, no fixation was applied; a mild lysis was used (250 mM NaCl, 0.1%
Nonidet P-40, 5 mM EDTA, 50 mM HEPES, pH 7.0; supplemented with inhibitor cocktail) to separate
total soluble from chromatin-bound fractions as described before [55]. Soluble fractions were collected
after centrifugation; chromatin pellets were washed; all samples were sonicated before analysis (see:
Western analysis).
4.13. Senescence-Associated Beta-Galactosidase Staining
Murine or human skeletal elements were fixed (0.2% Glutaraldehyde, 24 h). Upon staining, tissues
were cleared using a series of clearing solutions containing 1% KOH in 0%, 20%, 50% and finally 100%
Glycerol. Human (HAC, SW1353), rabbit (CPO, kper) and mouse (ATDC5) cell lines were cultured and
differentiated as indicated above. Fixation and SA-βGAL staining was done as described before [54].
4.14. Mice, Tissue Histology
Mouse and human bone tissues were decalcified (0.3 M EDTA, pH 7.4; 1 week and 0.5 EDTA,
pH 7.8, 4 weeks). PRC1-epitopes were retrieved by boiling (20 min, 0.01 M Citrate buffer, pH 6.0;
passive cooling). Collagen epitope retrieval: digestion with 0.4% Hyaluronidase. Decalcified 7 micron
slices of RING1 +/+, +/− and −/− mice were stained for ECM collagens with Sirius-red. HZ-widths
were scored blinded by two independent investigators (n = 4, KO; n = 8, HE; n = 2, WT); statistical
analysis: standard t-test. Bone elements were fixed (24 h, 4% Formaldehyde), precleared (1–3 days,
1% KOH) and stained (overnight, Alcian Blue 0.14% w/v, Alizarin Red 0.12% w/v in 20% Glacial
Acetic Acid/80% Ethanol) and washed with 96% Ethanol. Tissues were cleared for more than 6 weeks
(see: SA-bGAL staining). Use of human surgical surplus material was in accordance to Medical Ethical
Review Committee guide lines (METC 08-4-021). All animal work was performed according to local
ethical guidelines for animal experimentation.
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Abbreviations
BMI1 B lymphoma Mo-MLV insertion region 1
BrdU bromo-deoxyuridine
ChIP chomatin immunoprecipitation
DDR DNA damage response
DPOL2 DNA polymerase 2
DPOLR2 RNA polymerase 2
DSB double strand DNA breaks
ERSS ER-stress signaling
GMNN geminin
H3K27me3 histon H3 Lysine 27 trimethylation
H3K9me3 histon H3 Lysine 9 trimethylation
HZ hypertrophic zone
IF immunofluorescence
KD knockdown
KMD Lysine demethylase
KMT Lysine methyl transferase
OE overexpression
OIS oncogene induced senescence
PHC2 Polyhomeotic 2
pid post-induction of differentiation
PRC Polycomb repressive complex
pre-HZ pre-hypertrophic zone
PZ proliferative zone
RING1 really interesting new gene 1A
RNF2 ring-finger protein 2
SA-bGAL senescence associated beta-galactosidase
SASP senescence-associated Secretory phenotype
shcon control shRNA
shRNA short hairpin RNA
SLR senescence like response
SMS senescence messaging secretome
TA transit amplification
TOP2A topoisomerase 2
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TrxG Trithorax group proteins
UPR unfolded protein response
yH2A.X H2A.X Serine 139 phosphorylation
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